These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2028562)

  • 41. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
    De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
    Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.
    Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
    J Urol; 1990 Nov; 144(5):1248-51. PubMed ID: 2122008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravesical bacillus Calmette-Guérin and second primary malignancies.
    Guinan P; Brosman S; DeKernion J; Lamm D; Williams R; Richardson C; Reitsma D; Hanna M
    Urology; 1989 May; 33(5):380-1. PubMed ID: 2711556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Towards an understanding of the mode of action of Bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin.
    van der Sloot E; Kuster S; Böhle A; Braun J; Wood WG
    Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):503-11. PubMed ID: 1333824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytological changes induced by intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
    Takashi M; Schenck U; Koshikawa T; Nakashima N; Ohshima S
    Urol Int; 2000; 64(2):74-81. PubMed ID: 10810268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
    Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
    Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer.
    Saint F; Patard JJ; Irani J; Salomon L; Hoznek A; Legrand P; Debois H; Abbou CC; Chopin DK
    Urology; 2001 Apr; 57(4):617-21; discussion 621-2. PubMed ID: 11306359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer.
    Honda S; Sakamoto Y; Fujime M; Kitagawa R
    Int J Urol; 1997 Jan; 4(1):68-73. PubMed ID: 9179670
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Complications of intravesical bacillus Calmette-Guerin: a case report.
    Gonzalez JA; Marcol BR; Wolf MC
    J Urol; 1992 Dec; 148(6):1892-3. PubMed ID: 1433632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.
    Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
    J Urol; 1992 Jun; 147(6):1636-42. PubMed ID: 1593713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
    Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Progression and recurrence in the prostate and upper urinary tract following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Wakabayashi Y; Okada Y; Mukumoto K; Hamaguchi A; Konishi T; Tomoyoshi T
    Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2146-51. PubMed ID: 8309122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.
    De Jong WH; De Boer EC; Van der Meijden AP; Vegt P; Steerenberg PA; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1990; 31(3):182-6. PubMed ID: 2337907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective study of efficacy of intravesical BCG alone in treatment of superficial bladder cancer.
    Mydlo JH; Usher SM; Camacho F; Freed S
    Urology; 1986 Sep; 28(3):173-5. PubMed ID: 3750596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Urinary leukocytes as a new prognostic marker of therapeutic response and of adverse effects associated with the maintenance treatment with endovesical BCG, for the prophylaxis of superficial bladder tumors].
    Saint F; Irani J; Salomon L; Legrand P; Abbou CC; Chopin D
    Prog Urol; 2001 Dec; 11(6):1242-50. PubMed ID: 11859659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
    de Boer EC; De Reijke TM; Schamhart DH; Vos PC; Kurth KH
    Urol Res; 1993; 21(6):423-7. PubMed ID: 8171765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.